Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588586 | 0.82 | ALDH1A1 (1.00) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL691885 | 0.82 | ALDH1A1 (0.73) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3589713 | 0.81 | ALDH1A1 (1.00) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3590997 | 0.78 | ALDH1A1 (0.67) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL302929 | 0.77 | ATAD2 (0.70) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL3587356 | 0.77 | ALDH1A1 (0.51) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL2072823 | 0.76 | ATAD2 (0.68) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL303321 | 0.76 | ATAD2 (1.00) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL14433818 | 0.74 | ALDH1A1 (0.52) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL12415755 | 0.73 | ATAD2 (0.65) | ALDH1A1NPC1SMN1; SMN2KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | claimed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | claimed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | claimed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | claimed |
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | ALDH1A1 927/4885NPC1 305/4885SMN1; SMN2 1323/4885 |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | ALDH1A1 910/4885NPC1 298/4885SMN1; SMN2 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.